EU vs. US Supplement Validation Requirements: What Founders Need to Know

EU vs. US Supplement Validation Requirements: What Founders Need to Know

A claim that's perfectly defensible in the US can be a compliance problem in Germany, and vice versa. For supplement and wellness brands operating — or planning to operate — in both markets, this isn't a minor footnote. It's a structural difference in how the two systems decide what a brand is allowed to say, and it catches out even experienced marketing teams who assume "we have the evidence" is a universal answer.

Here's the practical version of how the two systems actually differ, and what it means for how you plan your validation work.

The core structural difference

In the US, the FTC operates on a case-by-case evidentiary standard: "competent and reliable scientific evidence," scaled to the specificity of the claim. There is no pre-approved list of allowed claims. You (and your legal counsel) assess whether your evidence supports what you're saying, and the FTC can challenge that assessment after the fact, typically through enforcement action if a claim turns out to be unsubstantiated or misleading.

In the EU, the system runs the opposite direction. Health claims are governed by a closed, pre-approved list maintained through EFSA and the Nutrition and Health Claims Regulation. You generally cannot make a novel health claim just because you have good evidence for it - the claim itself needs to be on the approved register, or go through a formal (and lengthy) EFSA submission process to get there. Evidence quality matters enormously for getting onto that list, but it doesn't function the same way as the US "build your own case" model.

This means: strong consumer research can be sufficient, appropriately used, evidence for a US structure/function claim - and simultaneously insufficient, on its own, to unlock a new claim in the EU, where the claim wording itself is the regulated object, not just the underlying evidence.

What this means for validation strategy

If you're building a claims and evidence strategy for a single market, the path is relatively linear: understand that market's standard, design research (consumer trial, clinical trial, or a combination) that meets it, and draft claim language accordingly.

If you're building for both markets - which is increasingly the default for European supplement and skincare brands with US ambitions, or US brands entering the German/EU market - a few practical implications follow:

- Design your consumer study to serve both purposes where possible. A well-structured study with validated PROs, a real panel, and a defined observation period can support US structure/function claim language directly, while also serving as supporting evidence in an EU claims dossier, even if it can't unlock a new EU claim on its own.

- Draft claim language separately for each market. The same underlying data will often need to be translated into different final claim wording - precise, pre-approved language for the EU; evidence-proportionate but more flexible language for the US.

- Budget the EFSA path realistically if you need a novel claim in Europe. It is a genuinely different scope of work from US substantiation - formal submission, EFSA scientific review, and timelines measured in a different order of magnitude than a consumer study.

- Don't assume "clinically studied" claims translate. A US brand's "clinically studied to support X" marketing language often can't be used as-is in EU marketing without checking it against the authorized claims register. This is one of the more common compliance gaps we see brands walk into during EU expansion.

Skincare follows the same logic

The claim-substantiation gap is just as real for skincare and cosmetics as for ingestible supplements. In the EU, cosmetic claims are governed by the EU Cosmetics Regulation and its own evidence framework (distinct from, though related to, the food supplement claims regime), while in the US, cosmetic claims fall under FTC and FDA guidance with their own standards for what "clinically proven" or "dermatologist tested" actually requires as backing. A brand making efficacy claims - visible reduction in fine lines, improved skin barrier function, reduced redness - needs evidence appropriate to both the specific claim and the specific jurisdiction it's being made in.

Where to start

If you're only operating in one market right now, start with the framework specific to it: our EFSA health claim types guide for the EU side, or How to Substantiate a Supplement Claim Without a Clinical Trial for the broader evidence framework that underpins US structure/function claims. If you're building for both, the right move is usually to design one well-built consumer study that's structured to serve both purposes from the start, rather than running separate research for each market.

Validence Labs designs consumer research for supplement and skincare brands operating across German/EU and US regulatory frameworks. Get in touch to talk through a validation strategy that works for both markets.

Validence Labs

We specialize in consumer insight studies and biomarker-supported consumer research for supplements, skincare, wellness, and functional products. Based in Germany and serving clients across the world, we help brands validate claims, understand customers, and make data-driven decisions.

Contact

info@validencelabs.com

© 2026. All rights reserved.

Privacy Policy

Terms and Conditions